

# Pre-Exposure Prophylaxis (PrEP) by the Numbers

Efficacy, regulatory  
approval and more



AUGUST 2016  
[avac.org](http://avac.org)

# Pre-Exposure Prophylaxis (PrEP) by the Numbers


PrEP is the use of ARVs to reduce HIV risk in people who are HIV-negative. Daily oral PrEP, the one form of PrEP proven to work today, is recommended by the World Health Organization as an additional option for all people at substantial risk of HIV. In spite of this endorsement and the need for new tools, different countries are moving at different speeds. Many are looking to demonstration projects—small-scale pilots that provide information on how to deliver oral PrEP in real-world settings. Advocates will look to countries to develop policies and plans to expand PrEP access. Now is the time to take regulatory action, learn from demonstration projects and fast-track plans for scale-up. Other formulations of ARV-based prevention are also being evaluated and could provide additional options in the future.

## Efficacy, regulatory status and more

### PrEP Works if You Take It — Effectiveness and Adherence in Trials of Oral and Topical Tenofovir-Based Prevention


Trials of oral and topical tenofovir-based PrEP show that these strategies reduce risk of HIV infection if they are used correctly and consistently. Higher adherence is directly linked to greater levels of protection.

Calculations based on analyses involving a subset of total trial participants.



### A Global Look at PrEP Introduction


The numbers in the large circles represent global totals, many of which took years to achieve, while the smaller circles represent changes in just under a year (since Oct '15). In sub-Saharan Africa, many of the implementation studies are in female sex workers—leaving gaps in research on men who have sex with men, adolescent girls and young women, and other groups in need.



### ARV-Based Prevention Pipeline

The pipeline of ARV-based prevention products includes oral pills, vaginal rings, vaginal and rectal gels, vaginal films, long-acting injectable ARVs. Not pictured are a range of multipurpose technologies in development that aim to reduce women's risk of HIV and STIs, and provide effective contraception.

For up-to-date information on the ARV-based prevention pipeline, visit the HIV Prevention Research Database at [www.avac.org/pxrd](http://www.avac.org/pxrd).





[www.avac.org](http://www.avac.org)

Founded in 1995, AVAC is an international, non-profit organization that uses education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of biomedical HIV prevention options as part of a comprehensive response to the pandemic.

AVAC is based in the US, and focuses on issues and priorities in countries where prevention research and implementation are ongoing. Specifically, we seek to deliver proven HIV prevention tools for immediate impact; demonstrate and roll out new HIV prevention options; and develop long-term solutions needed to end the epidemic.